Tanezumab and Nerve Function In Arthritis Patients

NCT ID: NCT00863772

Last Updated: 2021-02-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-18

Study Completion Date

2010-11-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tanezumab reduces pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was terminated on 16 Nov 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tanezumab 5 mg

Group Type EXPERIMENTAL

tanezumab

Intervention Type BIOLOGICAL

5 mg dose Intravenously every 8 weeks for duration of study

Tanezumab 10 mg

Group Type EXPERIMENTAL

tanezumab

Intervention Type BIOLOGICAL

10 mg dose Intravenously every 8 weeks for duration of study

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo, Intravenously, every 8 weeks for duration of study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tanezumab

5 mg dose Intravenously every 8 weeks for duration of study

Intervention Type BIOLOGICAL

tanezumab

10 mg dose Intravenously every 8 weeks for duration of study

Intervention Type BIOLOGICAL

Placebo

Placebo, Intravenously, every 8 weeks for duration of study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI less or equal to 39 kg/m2
* Osteoarthritis (arthritis) of the knee or hip with pain score that qualifies
* Willing to comply with study visit schedule and study requirements, including, for women of child-bearing potential or male patients with female partners of child-bearing potential, the use of 2 forms of birth control, one of which is a barrier method.
* Patients must consent in writing to participate in the study.

Exclusion Criteria

* Untreated, uncontrolled diseases,
* Unwilling or unable to discontinue the use of prohibited medications, including other pain medications, during the screening period and during the study,
* Significant cardiac disease within the past 6 months
* Significant neurological disease (e.g. peripheral neuropathy, multiple sclerosis, stroke) or signs of neuropathy at screening
* Known bleeding disorder or anticoagulation therapy
* Planned surgery during the study period
* History of alcoholism or drug abuse in the past 2 years
* Unable to use acetaminophen
* Use of a biologic (including live vaccines, with the exception of Flumist) within the past 3 months
* Allergic reaction to a biologic or an antibody in the past
* Disqualifying laboratory values, including Hepatitis B or C, HIV or drug test
* Cancer in the past 5 years. Basal cell or squamous cell carcinoma are okay.
* Medical condition that may interfere with study endpoints or safety of the subject as determined by the investigator.
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

NEA Baptist Clinic

Jonesboro, Arkansas, United States

Site Status

JDP Medical Research, LLC

Aurora, Colorado, United States

Site Status

Alpine Neurology

Centennial, Colorado, United States

Site Status

Peak Anesthesia

Centennial, Colorado, United States

Site Status

JEM Research, LLC

Atlantis, Florida, United States

Site Status

Medical Specialists of the Palm Beaches

Atlantis, Florida, United States

Site Status

Bradenton Research Center, Inc

Bradenton, Florida, United States

Site Status

Manatee Internal Medicine

Bradenton, Florida, United States

Site Status

Clinical Physiology Associates

Fort Myers, Florida, United States

Site Status

Harris Bonnette, MD

Fort Myers, Florida, United States

Site Status

Sunrise Clinical Research, Inc.

Hollywood, Florida, United States

Site Status

Sunrise Clinical Research, Inc

Hollywood, Florida, United States

Site Status

Pharmax Research Clinic, Inc

Miami, Florida, United States

Site Status

International Research Associates, LLC

Miami, Florida, United States

Site Status

The Arthritis Center

Palm Harbor, Florida, United States

Site Status

Pines Neurological Associates

Pembroke Pines, Florida, United States

Site Status

Pembroke Clinical Trials

Pembroke Pines, Florida, United States

Site Status

Pines Neurological Associates

Pembroke Pines, Florida, United States

Site Status

Advent Clinical Research Centers, Inc

Pinellas Park, Florida, United States

Site Status

Advent Clinical Research Center

Pinellas Park, Florida, United States

Site Status

Berma Research Group

Plantation, Florida, United States

Site Status

Kennedy-White Orthopaedic Center

Sarasota, Florida, United States

Site Status

Ronal Aung-Din, MD

Sarasota, Florida, United States

Site Status

Ronald Aung-Din, MD

Sarasota, Florida, United States

Site Status

Sarasota Center for Clinical Research

Sarasota, Florida, United States

Site Status

Arthritis & Rheumatic Care Center

South Miami, Florida, United States

Site Status

Miami Research Associates

South Miami, Florida, United States

Site Status

Neuroscience Consultants, LLC

South Miami, Florida, United States

Site Status

Carol L. Pappas MD, PhD

St. Petersburg, Florida, United States

Site Status

Carol L. Pappas, M.D. PhD

St. Petersburg, Florida, United States

Site Status

Dale G. Bramlet, MD, P.L.

St. Petersburg, Florida, United States

Site Status

Tampa Neurology Associates

Tampa, Florida, United States

Site Status

Tampa Medical Group, P.A.

Tampa, Florida, United States

Site Status

Radiology Associates of Venice & Englewood

Venice, Florida, United States

Site Status

Lovelace Scientific Resources, Inc

Venice, Florida, United States

Site Status

Venice Arthritis Center

Venice, Florida, United States

Site Status

Atlanta Center for Medical Research

Atlanta, Georgia, United States

Site Status

Atlanta Neurology

Atlanta, Georgia, United States

Site Status

Diagnostic Imaging of Atlanta

Atlanta, Georgia, United States

Site Status

NeuroTrials Research, Incorporated

Atlanta, Georgia, United States

Site Status

Northwest Neurology, P.C.

Austell, Georgia, United States

Site Status

Atlanta Knee and Sports Medicine

Decatur, Georgia, United States

Site Status

Joseph D. Weissman, MD

Decatur, Georgia, United States

Site Status

Neurology Specialists of Decatur

Decatur, Georgia, United States

Site Status

Southeastern Center for Clinical Trials

Decatur, Georgia, United States

Site Status

Jefrey D. Lieberman, MD

Decatur, Georgia, United States

Site Status

Northwestern Lake Forest Hospital Diagnostic Imaging Centers

Bannockburn, Illinois, United States

Site Status

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Consultants in Neurology, Ltd.

Northbrook, Illinois, United States

Site Status

Elkhart Clinic, LLC

Elkhart, Indiana, United States

Site Status

Indiana University School of Medicine

Indianapolis, Indiana, United States

Site Status

University Hospital

Indianapolis, Indiana, United States

Site Status

Mayo Clinic Rochester

Rochester, Minnesota, United States

Site Status

G. Timothy Kelly, MD

Las Vegas, Nevada, United States

Site Status

Clinical Neurology Specialists

Las Vegas, Nevada, United States

Site Status

Neurological Associates of Long Island, P.C.

Lake Success, New York, United States

Site Status

Andrew J. Porges, M.D. PC

Roslyn, New York, United States

Site Status

Asheville Imaging

Asheville, North Carolina, United States

Site Status

Biltmore Medical Associates

Asheville, North Carolina, United States

Site Status

Clinical Study Center of Asheville, LLC

Asheville, North Carolina, United States

Site Status

Asheville Neurology

Asheville, North Carolina, United States

Site Status

Unifour Medical Research Associates, LLC

Hickory, North Carolina, United States

Site Status

Neurology Associates, PA

Hickory, North Carolina, United States

Site Status

Unifour Medical Research Associates, LLC

Hickory, North Carolina, United States

Site Status

Caldwell Memorial Hospital

Lenoir, North Carolina, United States

Site Status

Northstate Clinical Research

Lenoir, North Carolina, United States

Site Status

Ohio Research Center

Toledo, Ohio, United States

Site Status

Bend Memorial Clinic

Bend, Oregon, United States

Site Status

North Star Neurology

Bend, Oregon, United States

Site Status

Altoona Hospital Campus

Altoona, Pennsylvania, United States

Site Status

Blair Neurologic Associates

Altoona, Pennsylvania, United States

Site Status

Blair Medical Associates

Altoona, Pennsylvania, United States

Site Status

Blair Orthopedic Associates, Inc.

Altoona, Pennsylvania, United States

Site Status

Bon Secour Campus

Altoona, Pennsylvania, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Coastal Carolina Research Center in Goose Creek

Goose Creek, South Carolina, United States

Site Status

Tidewater Neurology

Goose Creek, South Carolina, United States

Site Status

AAMR Research Clinic, PA

Amarillo, Texas, United States

Site Status

Amarillo Diagnostic Clinic

Amarillo, Texas, United States

Site Status

Radiant Research, Inc.

Dallas, Texas, United States

Site Status

Dr. Michael Vengrow

Dallas, Texas, United States

Site Status

Foundation for Southwest Orthopedic Research

Houston, Texas, United States

Site Status

The Neurology Center

Houston, Texas, United States

Site Status

Paragon Research Center, LLC

San Antonio, Texas, United States

Site Status

Baptist M&S Imaging

San Antonio, Texas, United States

Site Status

Sun Research Institute

San Antonio, Texas, United States

Site Status

Christine L. Truitt, MD

San Antonio, Texas, United States

Site Status

Diagnostics Research Group

San Antonio, Texas, United States

Site Status

Neurodiagnostic Laboratories of San Antonio, Inc.

San Antonio, Texas, United States

Site Status

Neurodiagnostic Laboratories of San Antonio, Inc

San Antonio, Texas, United States

Site Status

Radiant Research Inc.

San Antonio, Texas, United States

Site Status

IntegraTrials, L.L.C

Arlington, Virginia, United States

Site Status

TLC Neurology, P.L.L.C

Arlington, Virginia, United States

Site Status

Virginia Hospital Center

Arlington, Virginia, United States

Site Status

Hypothe Test, LLC

Roanoke, Virginia, United States

Site Status

Northwest Clinical Research Center

Bellevue, Washington, United States

Site Status

Evergreen Neurology and Neurodiagnostics, PLLC

Everett, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Brown MT, Cornblath DR, Koltzenburg M, Gorson KC, Hickman A, Pixton GC, Gaitonde P, Viktrup L, West CR. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clin Drug Investig. 2023 Jul;43(7):551-563. doi: 10.1007/s40261-023-01286-3. Epub 2023 Jul 18.

Reference Type DERIVED
PMID: 37460782 (View on PubMed)

Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.

Reference Type DERIVED
PMID: 30936738 (View on PubMed)

Brown MT, Herrmann DN, Goldstein M, Burr AM, Smith MD, West CR, Verburg KM, Dyck PJ. Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J Neurol Sci. 2014 Oct 15;345(1-2):139-47. doi: 10.1016/j.jns.2014.07.028. Epub 2014 Jul 18.

Reference Type DERIVED
PMID: 25073573 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NERVE SAFETY STUDY

Identifier Type: OTHER

Identifier Source: secondary_id

A4091026

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

INCB047986 in Rheumatoid Arthritis
NCT02151474 TERMINATED PHASE2